Published in J Clin Invest on September 01, 2004
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol (2010) 2.38
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog (2013) 1.65
Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther (2009) 1.54
Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med (2014) 1.51
Complete differentiation of CD8+ T cells activated locally within the transplanted liver. J Exp Med (2006) 1.25
Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation (2008) 1.20
Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology (2008) 1.11
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest (2013) 1.10
Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells. J Hepatol (2008) 1.10
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis (2010) 1.04
Liver immunology. Compr Physiol (2013) 0.99
Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun (2009) 0.98
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis. J Immunol (2012) 0.95
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest (2013) 0.91
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 0.90
The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors. World Allergy Organ J (2008) 0.90
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B (2014) 0.89
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci U S A (2014) 0.89
Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol (2016) 0.88
Malaria and the liver: immunological hide-and-seek or subversion of immunity from within? Front Microbiol (2015) 0.88
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
DAP12 promotes IRAK-M expression and IL-10 production by liver myeloid dendritic cells and restrains their T cell allostimulatory ability. J Immunol (2011) 0.87
Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system. PLoS One (2009) 0.86
HBV-Specific Adaptive Immunity. Viruses (2009) 0.85
Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury. J Virol (2005) 0.83
Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol (2009) 0.83
Induction of intrahepatic HCV NS4B, NS5A and NS5B-specific cellular immune responses following peripheral immunization. PLoS One (2012) 0.82
Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver. Hum Vaccin (2011) 0.82
Mouse liver-specific CD8(+) T-cells encounter their cognate antigen and acquire capacity to destroy target hepatocytes. J Autoimmun (2012) 0.80
The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. Front Immunol (2015) 0.80
Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis (2013) 0.80
Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med (2014) 0.79
Effector CD8 T cell trafficking within the liver. Mol Immunol (2012) 0.79
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Protective immunity to liver-stage malaria. Clin Transl Immunology (2016) 0.78
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res (2017) 0.78
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 0.78
Effective intrahepatic CD8+ T-cell immune responses are induced by low but not high numbers of antigen-expressing hepatocytes. Cell Mol Immunol (2015) 0.77
The role of hepatic immune regulation in systemic immunity to viral infection. Med Microbiol Immunol (2014) 0.77
Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions. BMC Gastroenterol (2013) 0.77
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat (2010) 0.77
Balance of inflammatory pathways and interplay of immune cells in the liver during homeostasis and injury. EXCLI J (2014) 0.76
Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J Gastroenterol (2013) 0.76
Immunoregulation of hepatitis B virus infection--rationale and clinical application. Nagoya J Med Sci (2012) 0.76
Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect? Clin Dev Immunol (2013) 0.76
Organ-specific differences in achieving tolerance. Curr Opin Organ Transplant (2015) 0.76
Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver. Transplantation (2016) 0.75
The CD8 T-cell response during tolerance induction in liver transplantation. Clin Transl Immunology (2016) 0.75
A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic mice. Nat Commun (2016) 0.75
Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models? Int J Mol Sci (2016) 0.75
The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Mol Ther (2017) 0.75
The role of liver sinusoidal cells in local hepatic immune surveillance. Clin Transl Immunology (2016) 0.75
The Role of Lymphatic Endothelial Cells in Liver Injury and Tumor Development. Front Immunol (2016) 0.75
CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. Proc Natl Acad Sci U S A (2017) 0.75
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol (2001) 9.23
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med (1990) 5.54
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
Hepatic T cells and liver tolerance. Nat Rev Immunol (2003) 3.51
Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med (2000) 3.25
High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today (1995) 2.95
Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell (1991) 2.83
Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans. J Exp Med (2000) 2.29
Selective retention of activated CD8+ T cells by the normal liver. J Immunol (1999) 2.23
The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity (1994) 2.11
Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med (2002) 2.02
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation (1980) 1.71
High-dose/activation-associated tolerance: a mechanism for allograft tolerance. Transplantation (1997) 1.65
Mechanisms of L-selectin regulation by activated T cells. J Immunol (1997) 1.64
Expression of two alpha chains on the surface of T cells in T cell receptor transgenic mice. J Exp Med (1993) 1.53
Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol (2001) 1.47
Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol (1998) 1.47
Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter. Proc Natl Acad Sci U S A (1989) 1.44
Activation induces rapid and profound alterations in the trafficking of T cells. Eur J Immunol (2000) 1.41
Peripheral deletion of autoreactive CD8+ T cells in transgenic mice expressing H-2Kb in the liver. Eur J Immunol (1995) 1.40
Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. Int Immunol (1992) 1.32
Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol (1997) 1.27
Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol (1998) 1.24
CTL access to tissue antigen is restricted in vivo. J Immunol (1994) 1.22
The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology (2001) 1.18
Recirculation, phenotype and functions of lymphocytes in mice treated with monoclonal antibody MEL-14. Eur J Immunol (1994) 1.18
Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol (2002) 1.16
Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol (2002) 1.10
Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology (2002) 1.05
Death by neglect as a deletional mechanism of peripheral tolerance. Int Immunol (1999) 1.03
The effect of portacaval shunt on delayed-hypersensitivity responses following antigen feeding. J Surg Res (1989) 1.03
The monoclonal antibody MEL-14 can block lymphocyte migration into a site of chronic inflammation. Eur J Immunol (1992) 1.02
Deletion of spontaneous rat liver allograft acceptance by donor irradiation. Transplantation (1995) 1.00
Evidence that apoptosis of activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance. Transplantation (1999) 0.97
HCV immunology--death and the maiden T cell. Cell Death Differ (2003) 0.97
Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology (2000) 0.92
Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: a marriage made in heaven. Immunol Cell Biol (1999) 0.90
Subverting lymph node trafficking by treatment with the Mel-14 monoclonal antibody to L-selectin does not prevent an effective host response to Sendai virus. J Immunol (1995) 0.88
Confounding factors complicate conclusions in aly model. Nat Med (2001) 0.85
Regulation of activator protein-1 and NF-kappa B in CD8+ T cells exposed to peripheral self-antigens. J Immunol (2001) 0.83
Immune disorders of the liver and bile duct. Gastroenterol Clin North Am (1992) 0.82
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest (2007) 4.77
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg (2006) 3.77
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology (2006) 2.30
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol (2002) 1.59
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Approaching the promise of operational tolerance in clinical transplantation. Transplantation (2011) 1.54
Tissue removal by ultrasound evaluation (the TRUE study): the Jetstream G2 system post-market peripheral vascular IVUS study. J Invasive Cardiol (2011) 1.54
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol (2003) 1.54
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2low Bimhigh phenotype, poor CTL function and cell death. J Hepatol (2012) 1.48
Hereditary lysozyme amyloidosis: spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. Liver Transpl (2006) 1.46
Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol (2002) 1.39
Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol (2002) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Clinical evaluation of the BD ProbeTec™ Chlamydia trachomatis Qx amplified DNA assay on the BD Viper™ system with XTR™ technology. Sex Transm Dis (2011) 1.33
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol (2003) 1.28
Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop. J Nanopart Res (2008) 1.28
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology (2005) 1.25
The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J (2010) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophys Methods (2003) 1.23
Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol (2006) 1.19
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res (2004) 1.16
Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol (2002) 1.16
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
Intrahepatic immunity: a tale of two sites? Trends Immunol (2005) 1.11
Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology (2008) 1.11
Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol (2006) 1.08
Liver fibrosis: a balance of ACEs? Clin Sci (Lond) (2007) 1.08
Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol (2003) 1.08
Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta (2004) 1.06
Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. J Hepatol (2012) 1.05
Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology (2002) 1.05
Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol (2010) 1.04
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res (2004) 1.04
Fibroblast activation protein and chronic liver disease. Front Biosci (2008) 1.03
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
A Randomized Trial of Probation Case Management for Drug-Involved Women Offenders. Crime Delinq (2011) 1.01
Invading macrophages play a major role in the liver progenitor cell response to chronic liver injury. J Hepatol (2010) 1.00
Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. Transpl Immunol (2011) 0.98
Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol (2006) 0.98
Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease. J Hepatol (2008) 0.98
Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology (2003) 0.97
Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry (2003) 0.97
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer (2014) 0.95
Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant (2006) 0.94
Early intrahepatic antigen-specific retention of naïve CD8+ T cells is predominantly ICAM-1/LFA-1 dependent in mice. Hepatology (2005) 0.94
miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int (2014) 0.94
Inflammation and repair in viral hepatitis C. Dig Dis Sci (2008) 0.94
Multicenter study evaluating performance of the Smart Group B Streptococcus (GBS) assay using an enrichment protocol for detecting GBS colonization in patients in the antepartum period. J Clin Microbiol (2010) 0.93
The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem (2009) 0.93
An international comparison of the effect of policy shifts to organ donation following cardiocirculatory death (DCD) on donation rates after brain death (DBD) and transplantation rates. PLoS One (2013) 0.93
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J (2006) 0.91
Hepatic pseudocapillarization in aged mice. Exp Gerontol (2005) 0.91
Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl (2008) 0.91
Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. Liver Int (2007) 0.90
Non-oxidative metabolism of ethanol by rat pancreatic acini. Pancreatology (2004) 0.89
Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. J Hepatol (2006) 0.88
A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res (2011) 0.88
Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J Clin Invest (2015) 0.88
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood (2002) 0.88
Synthesis, characterization, and remodeling of weight-bearing allograft bone/polyurethane composites in the rabbit. Acta Biomater (2010) 0.87
Postmortem analysis following 71 months of deep brain stimulation of the subthalamic nucleus for Parkinson disease. J Neurosurg (2008) 0.87
Rapid group B streptococci screening using a real-time polymerase chain reaction assay. Obstet Gynecol (2008) 0.87
Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation (2009) 0.87
Advances in and the future of treatments for hepatitis C. Expert Rev Gastroenterol Hepatol (2014) 0.87
Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation (2002) 0.87
Investigating the effects of San Francisco's Treatment on Demand Initiative on a publicly-funded substance abuse treatment system: a time series analysis. J Psychoactive Drugs (2009) 0.86
Dipeptidyl peptidase IV gene family. The DPIV family. Adv Exp Med Biol (2003) 0.86
Targeting post-transcriptional control for drug discovery. RNA Biol (2009) 0.86
A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl (2004) 0.85